POWERFUL MISSION 

MRI relentlessly pursues innovative opportunities which accelerate the development of next-generation musculoskeletal treatments to improve the quality of lives of patients.

POWERFUL LEADERSHIP

Innovative treatments will only be found with the hard work and talent of committed and uniquely qualified individuals who work with dedication and urgency to make a difference in the lives of patients.

POWERFUL MODEL

We break down every barrier slowing musculoskeletal research and development so that better treatments may be brought to patients.  As an end-to-end solution to accelerate discovery, translation and implementation, we do everything we can to make sure the next generation of treatments is brought to patients as quickly as possible – from bridging discovery gaps through our innovative research portfolio and funding early-stage research, to developing novel business solutions which inject speed and efficiency into every step along the development pathway. Our model works.

POWERFUL COLLABORATION

By working closely with researchers, clinicians and partners in the biotech, pharmaceutical and the medical device industry, we help accelerate musculoskeletal treatments which are improving lives around the globe. We are at a turning point where we have the knowledge, the team and the methods to build upon this success and advance the next generation of treatments.

POWERFUL POTENTIAL We are reaching incredible milestones in advancing our innovative research portfolio of investigator-initiated trials as well as sponsored clinical trial programs to ensure that better, more effective treatments are brought to patients as soon as possible.

POWERFUL SERVICES Research funding is provided by donations as well as the high quality clinical research consulting services which we provide.  MRI provides next generation clinical research consulting services for the biotech, pharmaceutical and medical device industries with an innovative, cost-effective approach which produces only high-quality, expedited results.

Because we are also intimately aware of the dire funding need for blood cancer research, a portion of all research service proceeds is donated to the Leukemia and Lymphoma Society in order to concommitantly expedite blood cancer research innovation and implementation for patients and their families.